PreHevbrio: the first approved 3-antigen hepatitis B vaccine

The persistence of seroprotective levels of antibodies after vaccination with PreHevbrio, a 3-antigen hepatitis B vaccine

(2023) T. Vesikari et al.   VACCINE

Universal Hepatitis B Vaccination in Adults Aged 19–59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

(2022) Mark K. Weng et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

The Global Impact of Hepatitis B Vaccination on Hepatocellular Carcinoma

(2022) Joan Ericka Flores et al.   Vaccines

Rapid and high seroprotection rates achieved with a tri-antigenic Hepatitis B vaccine in healthy young adults: Results from a Phase IV study

(2021) Jacob Atsmon et al.   VACCINE

Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial

(2021) Timo Vesikari et al.   LANCET INFECTIOUS DISEASES

Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac®, compared with Engerix-B® in healthy Asian adults: A phase 3 randomized clinical trial

(2021) Francisco Diaz-Mitoma et al.   VACCINE

Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine

(2021) Timo Vesikari et al.   JAMA Network Open

Hepatitis A and hepatitis B vaccination coverage among adults with chronic liver disease

(2018) Xin Yue et al.   VACCINE

Sci-B-VacTMVs ENGERIX-B Vaccines for Hepatitis B Virus in Patients with Inflammatory Bowel Diseases: A Randomised Controlled Trial

(2016) Ohad Etzion et al.   Journal of Crohns & Colitis

Hepatitis B vaccine response in obesity: A meta-analysis

(2016) Wei Fan et al.   VACCINE

Factors influencing immunologic response to hepatitis B vaccine in adults

(2016) Shigui Yang et al.   Scientific Reports

Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18–70 years of age

(2015) Julia M. Janssen et al.   VACCINE

Comparing vaccines: A systematic review of the use of the non-inferiority margin in vaccine trials

(2015) R. Donken et al.   VACCINE

Management of acute hepatitis B and reactivation of hepatitis B

(2013) Ankur Jindal et al.   LIVER INTERNATIONAL

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age

(2013) William L. Heyward et al.   VACCINE

Immune Response of Hepatitis B Vaccine Among Persons With Diabetes: A systematic review of the literature

(2012) S. F. Schillie et al.   DIABETES CARE

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

(2012) Rafael Lozano et al.   LANCET

Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

(2012) Benjamin P. Sablan et al.   VACCINE

Pathogenesis of hepatitis B virus infection

(2010) F.V. Chisari et al.   PATHOLOGIE BIOLOGIE

Anti-preS responses influence the anti-HBs response in newborns after vaccination with the third generation Sci-B-Vac™ vaccine

(2009) Staffan P.E. Sylvan et al.   VACCINE

PreS1 epitope recognition in newborns after vaccination with the third-generation Sci-B-Vac™ vaccine and their relation to the antibody response to hepatitis B surface antigen

(2009) Ulla B Hellström et al.   Virology Journal